Subscribe
T. Schneider / Shutterstock.com
21 May 2024NewsBiotechnologyLiz Hockley

USPTO appeals panel cements key claims position in antibody case

ARP maintained rejection of two claims of Xencor’s antibodies patent application | Panel clarified specification for means-plus-function claim limitations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool